Shaw Alan R
Merck Vaccine Division, West Point, PA 19486, USA.
Gynecol Oncol. 2005 Dec;99(3 Suppl 1):S246-8. doi: 10.1016/j.ygyno.2005.07.097. Epub 2005 Oct 5.
There are some 30-40 genotypes of human papillomavirus (HPV) that cause anogenital lesions in humans, primarily cervical, vaginal, and vulvar dysplasias and cancer in women, anal dysplasias in some men, and genital warts in both sexes.
Both GlaxoSmithKline and Merck companies are developing vaccines for the prevention of HPV infection.
Both vaccines stimulate an antibody response against HPV types 16 and 18; the Merck vaccine also include HPV types 6 and 11.
This report focuses on progress with both prophylactic vaccines and introduces strategies for global immunization.
约有30 - 40种人类乳头瘤病毒（HPV）基因型可导致人类肛门生殖器病变，主要是女性的宫颈、阴道和外阴发育异常及癌症，部分男性的肛门发育异常，以及男女两性的生殖器疣。
葛兰素史克公司和默克公司都在研发预防HPV感染的疫苗。
两种疫苗均能刺激针对16型和18型HPV的抗体反应；默克公司的疫苗还包括6型和11型HPV。
本报告重点介绍了两种预防性疫苗的进展情况，并介绍了全球免疫策略。
